Edoc Acquisition Corp.
Definitive Agreement
Follow
Detailed Information
Information on this SPAC.
- Sponsors
- IPO Size
- $100M
- Underwriters
- Focus
- Healthcare, Telemedicine, Technology, Artificial Intelligence
- SEC Filings
- 1824884
- Public Embarc Page
- https://embarc.com/capital/spac/1824884/ADOC/edoc-acquisition
SPAC Leadership
Information on the SPAC leadership.
- Chairman of the Board of Directors and Chief Executive OfficerKevin Chen
- Chief Financial Officer and DirectorChristine Zhao
- DirectorBob Ai
- DirectorGang Li
- DirectorJiuji Yan
- Xiaoping Becky Zhang
Target Information
Information on the SPAC target for merger.
- Company
- Australian Oilseeds Investments
- Presentation
- Investor Presentation (SEC) on 2022-02-02
- Description
- Calidi Biotherapeutics, Inc. is "a clinical-stage biotechnology company that is pioneering the development of cell-based delivery of oncolytic viruses."